Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system.
The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had to use a separate device to connect data from the sensor to their phones.
The app provides users with an eight-hour glucose history, as well as reports showing trends and patterns in users’ glucose control.
Abbott said the FreeStyle LibreLink app will be available to download via the Apple App Store in the coming weeks. The company is still working on an Android version of the app.
“We’re committed to liberating people from the many hassles of diabetes management through our life-changing technology and tools,” Jared Watkin, SVP of Abbott’s diabetes business, said in prepared remarks.
“The FreeStyle LibreLink app is a digital health tool that integrates glucose data directly on a compatible smartphone so all of the mobile apps that people use every day are in one convenient place. This is another step forward in making glucose monitoring seamlessly fit into a patient’s daily lifestyle – helping them live a fuller, healthier life,” Watkin added.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.